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Adiponectin is exclusively expressed in differentiated
adipocytes and plays an important role in regulating
energy homeostasis, including the glucose and lipid me-
tabolism associated with increased insulin sensitivity.
However, the control of adiponectin gene expression in
adipocytes is poorly understood. We show here that lev-
els of adiponectin mRNA and protein are reduced in the
white adipose tissue of ob/ob and db/db mice and that
there is a concomitant reduction of the adipocyte de-
termination- and differentiation-dependent factor 1
(ADD1)/sterol regulatory element-binding protein 1c
(SREBP1c) transcription factor. To determine whether
ADD1/SREBP1c regulates adiponectin gene expression,
we isolated and characterized the mouse adiponectin
promoter. Analysis of the adiponectin promoter re-
vealed putative binding sites for the adipogenic tran-
scription factors ADD1/SREBP1c, peroxisomal prolif-
erator-activated receptor  and CCAAT enhancer-
binding proteins. DNase I footprinting and chromatin
immunoprecipitation analyses revealed that ADD1/
SREBP1c binds in vitro and in vivo to the proximal pro-
moter containing sterol regulatory element (SRE) mo-
tifs. A luciferase reporter containing the promoter was
transactivated by ADD1/SREBP1c, and introduction of
SRE mutations into the construct abolished transactiva-
tion. Adenoviral overexpression of ADD1/SREBP1c also
elevated adiponectin mRNA and protein levels in 3T3-L1
adipocytes. Furthermore, insulin stimulated adiponec-
tin mRNA expression in adipocytes and augmented
transactivation of the adiponectin promoter by ADD1/
SREBP1c. Taken together, these data indicate that
ADD1/SREBP1c controls adiponectin gene expression in
differentiated adipocytes.
Adipose tissue is vital for maintaining whole body energy
homeostasis. It has traditionally been considered a mere en-
ergy depot, synthesizing and storing triglycerides during peri-
ods of caloric excess and releasing free fatty acids and glycerol
during periods of nutritional deprivation. However, it is now
recognized to play a more active role in regulating glucose and
lipid metabolism as an endocrine organ secreting biologically
active molecules, so called adipocytokines, that act on the cen-
tral nervous system and peripheral tissues (1).
Adiponectin (also known as Acrp30, AdipoQ, apM1, and
GBP28) is a member of the adipocytokine family that is exclu-
sively expressed in adipocytes (2–6). The mouse adiponectin gene
encodes 247 amino acids with two structurally distinct domains:
an N-terminal collagen-like fibrous domain and a complement
C1q-like globular domain at the C terminus (3). Adiponectin
forms oligomers and seems to circulate in the plasma as a ho-
motrimer or as larger complexes of 12 to 15 subunits. One of its
most interesting features, observed in rodents, monkeys, and
humans, is that its expression in adipose tissue and plasma is
reduced in obese and diabetic subjects (3, 7–11). Adiponectin
increases the insulin sensitivity associated with activation of
insulin signaling and glucose uptake (12, 13). Furthermore, ad-
ministration of full-length adiponectin lowers plasma glucose
levels by suppressing hepatic glucose production in obese and
diabetic mice (14). In addition, the globular domain of adiponec-
tin reduces elevated fatty acid levels in skeletal muscle by stim-
ulating fatty acid oxidation (13, 15). These insulin-sensitizing
effects seem to be mediated by AMP kinase (13, 15). Although
adiponectin-deficient mice are neither obese nor insulin-resistant
under basal conditions, they exhibit elevated levels of insulin,
free fatty acids, and glucose, together with insulin resistance,
when placed on a high fat diet (16, 17). Adiponectin is also
implicated in protection from atherosclerosis because its expres-
sion is reduced in patients with coronary artery disease (18–21).
Adiponectin decreases the attachment of monocytes to human
aortic endothelial cells, which represents an early stage of ath-
erosclerotic vascular damage, by lowering expression of several
adhesion molecules (18, 22). Furthermore, it reduces levels of
macrophage scavenger receptors so that they accumulate fewer
lipid droplets (19, 23). Yamauchi et al. (24) have cloned two
mouse adiponectin receptors, adiponectin receptors 1 and 2,
both of which have seven transmembrane domains. They are
abundantly expressed in skeletal muscle and liver, respec-
tively (24). It is likely that they serve as receptors for glob-
ular and full-length adiponectin, and mediate the increased
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AMP kinase and ligand-dependent PPAR1 activities in re-
sponse to adiponectin (24).
A number of factors have been reported to be positive or neg-
ative effectors of adiponectin expression. For instance, thiazo-
lidinediones, synthetic ligands of PPAR, increase both adiponec-
tin gene expression in adipocytes and circulating adiponectin
levels (25). Insulin and insulin-like growth factor 1 also increase
expression of adiponectin, whereas tumor necrosis factor 
(TNF), another adipocytokine, decreases adiponectin gene ex-
pression, suggesting a relationship to TNF-induced insulin re-
sistance (2, 26–28). Adiponectin mRNA expression is also sup-
pressed via protein kinase A by -adrenergic stimulation (28, 29).
However, there is little information about the transcription fac-
tors involved in adiponectin gene expression in adipocytes apart
from PPAR and liver receptor homolog-1 (30).
We report here that the expression of both adiponectin and
ADD1/SREBP1c was markedly decreased in the white adipose
tissue (WAT) of ob/ob or db/db mouse. To investigate whether
ADD1/SREBP1c directly regulates adiponectin expression, we
isolated and characterized the mouse adiponectin promoter.
Sequence analysis revealed putative binding sites for ADD1/
SREBP1c, PPAR, and C/EBPs, and DNase I footprinting and
chromatin immunoprecipitation (ChIP) assays demonstrated
that ADD1/SREBP1c binds to the promoter. Moreover, adeno-
viral overexpression of ADD1/SREBP1c increased adiponectin
expression and secretion in differentiated adipocytes, and this
effect was augmented by insulin. These observations indicate
that ADD1/SREBP1c is involved in insulin-stimulated adi-
ponectin expression in adipocytes.
EXPERIMENTAL PROCEDURES
Animal Treatment—Male C57BL/6 (10–12 weeks, 18–22 g), ob/ob,
and db/db mice were housed five mice/cage, and water was given ad
libitum, with a 12-h light-dark cycle beginning at 7:00 a.m. During
experiments, food was withdrawn in daylight hours (12 h). There were
four C57BL/6 mice in each feeding and fasting group. In the refeeding
experiment, food was reintroduced after 12 h of fasting. Animals were
sacrificed to isolate epididymal fat.
Northern Blot Analysis—Total RNA was isolated with TRIzol rea-
gent (Invitrogen) according to the manufacturer’s protocol. 20 g of
RNA was denatured in formamide and formaldehyde and separated by
electrophoresis on formaldehyde-containing agarose gels. After the
RNA was transferred to Nytran membranes, the membranes were
cross-linked, hybridized, and washed according to the manufacturer’s
recommendations (Schleicher and Schu¨ll). Probes were labeled by ran-
dom priming using the Klenow fragment of DNA polymerase I (Pro-
mega) and [-32P]dCTP (Amersham Biosciences). cDNAs used as probes
were as follows: ADD1/SREBP1c, adiponectin, PPAR, C/EBP, fatty
acid synthase (FAS) and adipose fatty acid-binding protein.
Western Blot Analysis—Fat tissue was lysed in TGN buffer with 50
mM Tris, pH 7.5, 150 mM NaCl, 1% Tween 20, 0.2% Nonidet P-40, 1 mM
phenylmethylsulfonyl fluoride, 500 mM NaF, 1 mM Na3VO4, 10 g/ml
aprotinin, 2 g/ml pepstatin A, and 10 g/ml leupeptin. Total cell
lysates were centrifuged at 12,000 rpm for 10 min to remove fat debris.
Supernatant protein concentrations were determined with the Bio-Rad
protein dye reagent. Total extracts (5080 g) were resolved by 10%
SDS-PAGE and transferred to polyvinylidene difluoride membranes
(Millipore). Western blot analysis was performed as recommended by
the manufacturer. Mouse adiponectin antibodies were kindly provided
by KOMED Inc. (Seoul, Korea) and Dr. T. L. Huh. Bound antibodies
were visualized by incubation with horseradish peroxidase-conjugated
secondary antibodies followed by enhanced chemiluminescence and
exposure to x-ray film.
DNase I Footprinting—The adiponectin promoter fragments (con-
taining bp 445 to 116) were isolated by double digestion with ApaI
and EcoRI to obtain 5- and 3-overhanging ends. They were labeled
with Klenow fragment and [-32P]dATP, then purified by PAGE. Bind-
ing experiments were performed with 50,000 cpm (1 ng) of probe per
reaction in a solution containing 10 mM HEPES, pH 7.9, 60 mM KCl, 7%
(v/v) glycerol, 1 mM EDTA, 1 mM dithiothreitol, 2 g of poly (dI-dC) 
poly(dI-dC), and the indicated amounts of recombinant ADD1/SREBP1c
protein overexpressed in E. coli as described previously (31). After 30
min of incubation on ice, 5 l of DNase I, freshly diluted in a solution
containing 10 mM HEPES, pH 7.9, 60 mM KCl, 25 mM MgCl2, 5 mM
CaCl2 and 7% (v/v) glycerol was added to the reaction, which was then
kept at room temperature for 2 min. The dilutions of DNase I ranged
from 1:200 to 1:2000 of stock (10 units/l), depending on the amount of
protein in the reaction. Digestion was stopped by the addition of 80 l
of a stop solution containing 20 mM Tris/HCl, pH 8.0, 20 mM EDTA, 250
mM NaCl, 0.5% SDS, 4 g of yeast tRNA, and 10 g of proteinase K. The
samples were incubated for 30 min at 45 °C, extracted with phenol/
chloroform, precipitated with ethanol and resuspended in formamide
dye. They were resolved on 6% (w/v) polyacrylamide/7 M urea sequenc-
ing gels, and the protected regions mapped with reference to the mi-
gration of Maxam-Gilbert AG sequencing products.
Cell Culture—3T3-L1 cells were grown in Dulbecco’s modified Ea-
gle’s medium (DMEM) supplemented with 10% fetal bovine serum
(HyClone) and 5% CO2 at 37 °C. Differentiation of preadipocytes to
adipocytes was achieved by allowing the cells to reach confluence and
adding DMEM supplemented with 10% fetal bovine serum, 0.5 mM
3-isobutyl-1-methylxanthine, 1 M dexamethasone, and 5 g/ml insulin
at 5% CO2 and 37 °C. Every 2 days thereafter, fresh medium (DMEM
plus 10% fetal bovine serum and 5 g/ml insulin) was added to the cells.
Rat1-IR and human embryonic kidney 293 cells were maintained in
DMEM supplemented with 10% (v/v) bovine calf serum (Jeil Biotech.
Inc., Daegu, South Korea) and 100 units of antibiotic-antimycotic and
were cultured at 37 °C in a 10% CO2 incubator.
Cloning of the Mouse Adiponectin Promoter and Construction of a
Luciferase Reporter—Mouse genomic DNA was isolated from 3T3-L1
cells with lysis buffer (50 mM Tris, pH 7.5, 50 mM EDTA, 100 mM NaCl,
and 2% SDS). Conditions for PCR were as follows 2 mM concentrations
of each primer, 0.6 mM concentrations of each dNTP, 1 PCR buffer, 5
units of LA (long amplification) Taq polymerase (TaKaRa), in a 50-l
reaction volume. The PCR cycle was: 30 s at 95 °C, followed by 30 cycles
of 12 s at 95 °C, 30 s at 60 °C, and 1 min at 72 °C, and then 5 min at
72 °C. The primers used were as follows: forward (984 bp), 5-GTT
GCA GTT GGC TGG TAC CCC AGA GCT AAT AAT AGA TAG-3;
forward (410 bp), 5-CCT GAA CCA CAC AGC TTC AC-3; reverse,
5-TTT TGG TGT CTC GAG ATC CAC TGA CAA TCG TAC AGA
CAG-3. The primers included KpnI (5-primer) and XhoI (3- primer)
restriction sites. The PCR products were digested with KpnI and XhoI,
and subcloned into pGEM easy vector (Promega) and pGL3-basic vector
(Promega). Site-directed mutagenesis of the adiponectin promoter
(410 bp)-Luc plasmids was performed with the QuikChange kit
(Stratagene) using the following mutagenic primers (mutated sites
underlined): mSRE1, 5-GAG TGG GAG TAT CAT GCG CCA ATT AGT
GTT GTT GAC TCT CCA GG-3; mSRE2, 5-CCA GGA CAA ACT TAT
GGG AAA GGG AGG TCT CCG GGC CCC TGA AC-3. Constructs were
confirmed by sequencing.
Transient Transfection and Luciferase Assay—Human embryonic
kidney 293 or Rat1-IR cells were transfected with DNA constructs 1 day
before confluence by the calcium phosphate method as described previ-
ously (31, 32). The mammalian expression vector for ADD1, containing
amino-terminal ADD1/SREBP1c from amino acids 1 to 403, was derived
from pSV-SPORT1 (Invitrogen) as described previously (31). After in-
cubation for 24 h, cell extracts were prepared with lysis buffer (25 mM
Tris-phosphate, pH 7.8, 2 mM dithiothreitol, 2 mM CDTA, 10% glycerol,
and 1% Triton X-100), and activities of -galactosidase and luciferase
were determined according to the manufacturer’s instructions (Pro-
mega). The luciferase activity of each sample, expressed in relative light
units, was normalized to its -galactosidase activity.
ChIP Assay—ChIP assays were performed as described previously
(33). In brief, differentiated 3T3-L1 cells were incubated with 200 nM
insulin for 48 h. The differentiated adipocytes were cross-linked in 1%
formaldehyde at 37 °C for 10 min and resuspended in 200 l of Nonidet
P-40-containing buffer (5 mM PIPES, pH 8.0, 85 mM KCl, and 0.5%
Nonidet P-40). Crude nuclei were precipitated and lysed in 200 l of
lysis buffer (1% SDS, 10 mM EDTA, and 50 mM Tris-HCl, pH 8.1), and
the nuclear lysates were sonicated and diluted 10-fold with immuno-
1 The abbreviations used are: PPAR, peroxisomal-activated receptor;
TNF, tumor necrosis factor ; ADD1, adipocyte determination- and
differentiation-dependent factor 1; SREBP1c, sterol regulatory ele-
ment-binding protein 1c; WAT, white adipose tissue; C/EBP, CCAAT
enhancer-binding protein; ChIP, chromatin immunoprecipitation; FAS,
fatty acid synthase; DMEM, Dulbecco’s modified Eagle’s medium;
CDTA, 1,2-diaminocyclohexane-N,N,N,N-tetraacetic acid; PIPES, 1,4-
piperazinediethanesulfonic acid; RT, reverse transcription; SCD-1, ste-
aroyl-CoA desaturase-1; PPRE, peroxisomal-activated receptor regula-
tory element; SRE, sterol regulatory element; GAPDH, glyceraldehyde
3-phosphate dehydrogenase.
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precipitation buffer (16.7 mM Tris-HCl, pH 8.1, 167 mM NaCl, 1.2 mM
EDTA, 0.01% SDS, and 1.1% Triton X-100). They were then incubated
with Protein A-Sepharose CL-4B (Amersham Biosciences) and anti-
ADD1 antibodies for 2 h at 4 °C. After successive washes, immunocom-
plexes containing DNA were eluted, and the precipitated DNA was
amplified by PCR. Conditions for PCR were as follows: 0.25 M concen-
trations of each primer, 0.1 mM concentrations of each dNTP, 1 PCR
buffer, 1 unit of Ex Taq polymerase (TaKaRa), 0.06 mCi/ml [-32P]dCTP
in a 20-l reaction volume. The products were resolved on 6% polyacryl-
amide/1 Tris-borate/EDTA gels. Primers used were as follows: 572
adiponectin-forward (f), 5-GGT GCT GGG AAT TGA ACT CA-3; 213
adiponectin-reverse (r), 5-CCT GTT TCC AGG CTT TGG CC-3; 349
PPAR2-f, 5-CTG TAC AGT TCA CGC CCC TC-3; 51 PPAR2-r,
5-TCA CAC TGG TGT TTT GTC TAT G-3; GAPDH-f, 5-GTG TTC
CTA CCC CCA ATG TG-3; GAPDH-r, 5-CTT GCT CAG TGT CCT
TGC TG-3.
Adenovirus Infection and Semiquantitative RT-PCR—Differentiated
3T3-L1 adipocytes were infected with 1 ml of adenovirus-containing
DMEM at a titer of 10 plaque-forming units per cell and incubated for
12 h at 37 °C. The culture medium was then adjusted to 2 ml with
DMEM supplemented with 10% fetal calf serum. After incubation for a
total of 48 h, cells were harvested for RNA isolation using TRIzol
reagent (Invitrogen) according to the manufacturer’s protocol. RT-PCR
reactions were performed with the SuperScript first-strand synthesis
system for RT-PCR kit (Invitrogen). ADD1/SREBP1c, adiponectin, FAS,
and stearoyl-CoA desaturase-1 (SCD-1) cDNAs were amplified for 30,
28, 29, and 29 (non-saturating) cycles, respectively. RT-PCR products
were analyzed by 0.7% agarose gel electrophoresis, and band intensities
were compared by imaging ethidium bromide staining (Scion Image;
Scion Corporation, Frederick, MD). Primers used were as follows:
ADD1/SREBP1c-f, 5-GGG AAT TCA TGG ATT GCA CAT TTG AA-3;
ADD1/SREBP1c-r, 5-CCG CTC GAG GTT CCC AGG AAG GGT-3;
adiponectin-f, 5-ATG CTA CTG TTG CAA GCT CTC-3; adiponectin-r,
5-GTT GGT ATC ATG GAA GAG AAG-3; FAS-f, 5-TGC TCC CAG
CTG CAG GC-3; FAS-r, 5-GCC CGG TAG CTC TGG GTG TA-3;
SCD-1-f, 5-TGG GTT GGC TGC TTG TG-3; SCD-1-r, 5-GCG TGG
GCA GGA TGA AG-3; GAPDH-f, 5-TGC ACC ACC AAC TGC TTA
G-3; GAPDH-r, 5-GGA TGC AGG GAT GAT GTT C-3.
RESULTS
Expression of Adiponectin and ADD1/SREBP1c in Obese and
Diabetic Mice—Previous studies have demonstrated that adi-
ponectin expression is significantly reduced in the WAT of
several obese and/or diabetic animal models (3, 34). To gain
insight into the control of adiponectin gene expression, we
investigated the expression of several adipogenic transcription
factors in the WAT of ob/ob and db/db mice. As shown in Fig. 1,
the expression of PPAR, C/EBP, and aP2 was not altered in
the WAT of mice. However, the level of ADD1/SREBP1c mRNA
was found to be substantially decreased, as was the level of
adiponectin mRNA (Fig. 1A). ADD1/SREBP1c protein levels
were also lower (Fig. 1B), indicating that ADD1/SREBP1c may
influence adiponectin expression in adipose tissue.
Binding of ADD1/SREBP1c to the Mouse Adiponectin Pro-
moter—To investigate the possibility that ADD1/SREBP1c is
involved in the regulation of adiponectin gene expression, we
cloned 0.98 kb of the mouse adiponectin promoter from
genomic DNA by PCR. Sequence analysis of the promoter re-
vealed several putative binding motifs for transcription factors
ADD1/SREBP1c, PPAR, C/EBPs, and nuclear factor Y (Fig.
2A). Two putative SREs and a putative peroxisomal prolifera-
tor-activated receptor regulatory element (PPRE) were present
from bp 400 to 330 and at bp 270, respectively. Two
C/EBP-binding sites were also located at bp 775 and 264
upstream of the transcription initiation site (Fig. 2A). The
promoter also contains several E-box motifs and nuclear fac-
tor-Y binding sites, as indicated in Fig. 2A. There is 55.9%
sequence identity between the proximal promoter regions of
mouse and human adiponectin promoters, and the SREs,
PPRE, and C/EBP-binding sites are relatively well conserved
(Fig. 2B).
To delineate the precise binding site(s), we performed a
DNase I footprinting analysis with recombinant ADD1/
SREBP1c protein (Fig. 3A). As shown in Fig. 3, two sites, SRE1
and SRE2, were protected from DNase I digestion (lanes 3–5).
SRE1 is located between bp398 and389 and SRE2 between
bp 343 and 334; both SRE motifs from the mouse adiponec-
tin promoter were well conserved with known SREs (Fig. 3B).
We also preformed gel shift assay with the mouse adiponectin
promoter (data not shown).
Transactivation of the Mouse Adiponectin Promoter by
ADD1/SREBP1c—We examined the ability of ADD1/SREBP1c
to transactivate the adiponectin promoter. Two luciferase re-
porter plasmids were constructed by inserting different 5-
flanking regions (bp984 and bp410) of the mouse adiponec-
tin promoter into pGL3 basic vector, yielding constructs
pAdiponectin-984-Luc and pAdiponectin-410-Luc, respectively.
Coexpression of ADD1/SREBP1c with these reporter con-
structs led to transcription of the adiponectin promoter (Fig.
4A). To determine which SRE(s) was responsible, we con-
structed mutant reporters bearing SRE mutations (Fig. 4B).
When SRE1 (mSRE1 pAdiponectin-410-Luc) or SRE2 (mSRE2
pAdiponectin-410-Luc) was disrupted, transactivation still oc-
curred. However, when both SRE1 and SRE2 were disrupted
(mSRE1 & 2 pAdiponectin-410-Luc), transactivation was no
longer observed, implying that either SRE1 or SRE2 is suffi-
cient for activation of the adiponectin promoter by ADD1/
SREBP1c (Fig. 4B).
PPAR and C/EBP are well known adipogenic transcription
factors that modulate expression of many adipocyte-specific
genes, and the mouse adiponectin promoter contains a poten-
tial PPRE, as well as C/EBP binding sites (Fig. 2). It has been
demonstrated recently that PPAR is involved in transcrip-
tional activation of the human adiponectin promoter. We there-
fore tested whether PPAR and C/EBP are involved in trans-
activation of the mouse promoter. We performed luciferase
FIG. 1. mRNA and protein profiles of adiponectin and ADD1/
SREBP1c in WAT of C57BL/6, db/, ob/ob, and db/db mice. mRNA
(A) and protein (B) levels in the WAT of each type of mouse were
examined by Northern or Western blot analysis, respectively. aP2,
adipose fatty acid-binding protein.
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reporter assays in human embryonic kidney 293 cells, which
seem to lack most adipogenic transcription factors. As shown in
Fig. 4C, coexpression of PPAR and retinoid X receptor (RXR)
 led to transactivation of the mouse promoter, and rosiglita-
zone, a synthetic PPAR ligand, further enhanced promoter
activity by activating PPAR (Fig. 4C, lanes 1 and 2). However,
transactivation by PPAR seemed to be less efficient than by
ADD1/SREBP1c (Fig. 4C). C/EBP completely failed to trans-
activate the mouse adiponectin promoter (Fig. 4D). Therefore,
it is likely that adiponectin expression in adipocytes may be
regulated by PPAR as well as by ADD1/SREBP1c.
Induction of Adiponectin mRNA Expression by ADD1/
SREBP1c—To see whether ADD1/SREBP1c controls adiponec-
tin gene expression in vivo, we overexpressed ADD1/SREBP1c
in differentiated 3T3-L1 adipocytes via adenovirus infection.
The level of adiponectin mRNA in the infected cells was ap-
proximately 2.7-fold higher than in control adipocytes not in-
fected with virus. Adenovirally overexpressed ADD1/SREBP1c
also enhanced expression of ADD1/SREBP1c target genes, in-
cluding FAS and SCD-1 (Fig. 5). Furthermore, expression of
FIG. 2. Putative binding sites of several transcription factors in the mouse adiponectin promoter (984 bp). A, the sequence of the
mouse adiponectin gene is shown and numbered from the transcription initiation site. Two putative SRE motifs, three E-boxes, one PPRE, two
C/EBP sites, nuclear factor-Y, and CCAAT are marked with arrows. B, schematic representation of the mouse and human adiponectin promoters.
The putative SREs (black ovals), C/EBP-binding sites (black squares), E-boxes (black triangles), and PPRE (black diamonds) are indicated.
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ADD1/SRBEP1c itself also increased, presumably via an auto-
regulatory loop (35, 36). These results demonstrate that ADD1/
SREBP1c is able to promote adiponectin expression in adipo-
cytes, at least at the level of transcription.
Adiponectin Gene Expression Is Influenced by Nutritional
Status and Insulin via ADD1/SREBP1c—Others and we have
demonstrated that expression of ADD1/SREBP1c is tightly reg-
ulated by nutritional status (32, 37, 38). Expression of SREBP1
mRNA in WAT was reduced by fasting and induced by feeding
or refeeding (Fig. 6A). To determine whether nutrition-depend-
ent expression of ADD1/SREBP1c might affect adiponectin ex-
pression, we measured adiponectin mRNA levels upon feeding,
fasting, and refeeding. When mice were fasted, adiponectin
mRNA expression proved to be low compared with normal
feeding or refeeding conditions (Fig. 6A). Thus, adiponectin
gene expression is also regulated by nutritional status and is
correlated with the regulation of ADD1/SREBP1c.
Insulin positively regulates the expression of ADD1/
SREBP1c in fat and liver. To examine the effect of insulin on
adiponectin expression, we treated differentiated 3T3-L1 adi-
pocytes with insulin. Expression of adiponectin mRNA, like
that of ADD1/SREBP1c, was stimulated by insulin (Fig. 6B).
Next, to see whether ADD1/SREBP1c is involved in insulin-de-
pendent adiponectin expression, we performed luciferase re-
porter assays in the absence and presence of insulin. Mouse
adiponectin promoter activity was not significantly changed by
insulin in the absence of ADD1/SREBP1c. However, it was
strongly stimulated (2–3-fold) by insulin in the presence of
ADD1/SREBP1c (Fig. 6C). To confirm that ADD1/SREBP1c
mediates this insulin-dependent adiponectin expression, we
performed ChIP assays. Nuclear lysates of differentiated adi-
pocytes incubated in the presence of insulin were immunopre-
cipitated with antibodies against ADD1/SREBP1c after form-
aldehyde cross-linking, and association of ADD1/SREBP1c
FIG. 3. Binding of ADD1/SREBP1c
to the mouse adiponectin promoter.
A, DNase I footprint of the mouse adi-
ponectin promoter. Lane 1, G/A ladder;
lanes 2 and 6, DNase I treatment of the
mouse adiponectin promoter in the ab-
sence of recombinant ADD1/SREBP1c
protein; lanes 3, 4, and 5, in the presence
of increasing concentrations of recombi-
nant ADD1/SREBP1c (0, 0.5, 1, or 2 g).
B, sequence comparison of putative SREs
in the mouse adiponectin promoter with
conserved SRE motifs.
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with the endogenous adiponectin promoter was assessed by
PCR amplification of pelleted DNA. Although ADD1/SREBP1c
clearly bound to the mouse adiponectin promoter without in-
sulin, its binding was substantially enhanced by insulin treat-
ment, as expected (Fig. 6D).
We also overexpressed ADD1/SREBP1c in differentiated
3T3-L1 adipocytes via adenovirus and examined adiponectin
protein levels by Western blot analysis (Fig. 7). Expression of
adiponectin protein was about 2.4-fold higher in ADD1/
SREBP1c-infected adipocytes than in control, uninfected adi-
pocytes (Fig. 7A, lanes 1 and 2). Insulin treatment also in-
creased the level of adiponectin protein, and ADD1/SREBP1c
enhanced this effect (Fig. 7A, lanes 3 and 4). Because adiponec-
tin is secreted by adipocytes, we sought to determine whether
FIG. 4. Transactivation of adiponectin by ADD1/SREBP1c. A, pAdiponectin-984-Luc or pAdiponectin-410-Luc reporters were cotransfected
together with an ADD1/SREBP1c expression vector (ADD1–403) and pCMV--gal into human embryonic kidney 293 cells. B, the adiponectin
promoter activity of ADD1/SREBP1c is dependent on two putative SRE motifs. pAdiponectin-410-Luc or mutant reporter genes were cotransfected
together with the ADD1/SREBP1c expression vector and pCMV--gal into human embryonic kidney 293 cells. C, ADD1/SREBP1c and PPAR
independently transactivate the mouse adiponectin promoter. The pAdiponectin-410-Luc reporter gene was transfected with ADD1 or PPAR
expression vector. After transfection, cells were incubated overnight in serum-free DMEM with 0.5% BSA and treated with or without 1 M
rosiglitazone for 24 h. DMSO, dimethyl sulfoxide; TZD, thiazolidinedione. D, C/EBP dose not transactivate the mouse adiponectin promoter. The
pAdiponectin-984-Luc reporter gene was transferred together with the C/EBP expression vector and pCMV--gal into human embryonic kidney
293 cells. Luciferase activities were normalized to -galactosidase activity and the values are expressed as fold activity relative to the control. Error
bars indicate standard deviations (n  3).
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ADD1/SREBP1c affects its secretion; this was indeed the case
(Fig. 7B). These results suggest that ADD1/SREBP1c regulates
adiponectin expression at the post-transcriptional as well as
the transcriptional level.
DISCUSSION
Adipose tissue expresses and secretes diverse adipocytokines
that affect lipid and glucose metabolism, feeding behavior,
energy balance, and insulin sensitivity. In obese subjects, de-
fined as having an accumulation of excess adipose tissue, adi-
pocytes are frequently enlarged so that the secretory profile of
the larger adipocytes becomes altered and increasingly dys-
regulated compared with that of smaller ones from normal
subjects. Thus, it has been suggested that defective regulation
of adipocytokines is closely related to metabolic disorders in
obesity. For example, TNF has been implicated in insulin
resistance (39–41). TNF mRNA and protein levels are ele-
vated in the adipose tissue of obese and type II diabetic animal
models and humans (39, 41, 42). Leptin, another adipocytokine,
suppresses food intake and stimulates energy expenditure, and
its expression is increased in obese animals, as is the recently
identified resistin (43–47). However, physiological roles of re-
sistin are not clearly understood. Although the levels of most
adipocytokines increase in obesity, because of the increase in
the total mass of body fat, adiponectin expression is reduced in
subjects with obesity, type 2 diabetes or atherosclerosis (3, 7–9,
21, 48). On the other hand, adiponectin administration induces
weight loss and improves insulin resistance by increasing fatty
acid utilization by activating AMP kinase and inhibiting he-
patic glucose production (13–15, 49).
Adiponectin gene expression is regulated by several extracel-
lular signals, including insulin, TNF, and -adrenergic ago-
nists, although the link between these signals and adiponectin
gene expression, in most cases, remains to be elucidated. For
instance, insulin stimulates the expression and secretion of adi-
ponectin in adipocytes, although there are some controversies.
Insulin is a key anabolic hormone regulating systemic energy
balance by coordinating the storage, mobilization, and utilization
of free fatty acids and glucose in liver, skeletal muscle, and
adipose tissue. The postprandial rise in plasma insulin increases
uptake of glucose and its conversion to glycogen and triglyceride
and suppresses glucose production. Therefore, it is of interest to
note that insulin stimulates expression of adiponectin and its
secretion from adipocytes (Figs. 6 and 7); increased expression of
adiponectin is essential to reverse insulin resistance, which oc-
curs when the body fails to respond properly to insulin and is an
important factor in the development of type 2 diabetes. Although
adiponectin reduces insulin resistance, it does not directly affect
insulin secretion or plasma insulin levels (14). Rather, it pro-
motes insulin sensitivity by several mechanisms, including im-
provement of insulin signaling, increase of fatty acid oxidation,
inhibition of gluconeogenesis, and suppression of TNF signaling
(14–16, 22).
ADD1/SREBP1c belongs to the SREBP family of basic helix-
loop-helix leucine-zipper transcription factors that play impor-
tant roles in lipid metabolism (31, 32, 50–52). SREBPs consist of
two proteins, SREBP1 and SREBP2 (52, 53). The SREBP1 gene
produces two isoforms, SREBP1a and SREBP1c, by use of alter-
native promoters (52, 54, 55). ADD1/SREBP1c is involved in
adipocyte differentiation, insulin sensitivity, and fatty acid me-
tabolism (32, 50, 51). It is highly expressed in adipose tissues and
liver, and its transcription is induced at an early stage of adipo-
cyte differentiation, suggesting a role in the induction of the
many adipogenic genes that orchestrate adipocyte differentiation
and lipid homeostasis (50, 51). In fact, ADD1/SREBP1c stimu-
lates the expression of many genes involved in lipogenesis and
adipogenesis including PPAR, FAS, acetyl CoA carboxylase,
lipoprotein lipase, and resistin (32, 33, 50, 56–60).
ADD1/SREBP1c mRNA expression and protein levels are
evidently down-regulated in obese and diabetic animal models
(Fig. 1). It has been reported that ADD1/SREBP1c expression
is decreased in adipose tissue of obese and diabetic humans and
that ADD1/SREBP1c expression was lower in obese mice when
the genome-wide gene expression profile was investigated (61–
63). As described above, mRNA and plasma levels of adiponec-
tin are also reduced in obese subjects (Fig. 1). Therefore, it is
likely that common signaling pathways exist to regulate both
adiponectin and ADD1/SREBP1c gene expression in adipocytes
and that ADD1/SREBP1c is an important transcription factor
mediating adiponectin gene expression.
Others and we have shown previously that the expression
level of ADD1/SREBP1c is tightly regulated by insulin and
nutritional status to coordinate lipid and glucose metabolism in
adipose tissue (32). Herein, we have shown that insulin-de-
pendent adiponectin expression is mediated by ADD1/
SREBP1c because insulin stimulated transactivation of the
adiponectin promoter by ADD1/SREBP1c (Fig. 6). Further-
more, ADD1/SREBP1c enhanced the synthesis and secretion of
adiponectin in differentiated adipocytes (Figs. 5 and 7), imply-
ing that ADD1/SREBP1c increases insulin sensitivity via its
FIG. 5. Induction of adiponectin mRNA by ADD1/SREBP1c. A,
ADD1/SREBP1c was overexpressed in differentiated 3T3-L1 adipocytes
by adenovirus infection. 3T3-L1 adipocytes were infected with adeno-
virus containing ADD1/SREBP1c or not, and total RNAs were isolated
and analyzed by semi-quantitative RT-PCR. B, quantitation of induced
mRNA levels of ADD1/SREBP1c, adiponectin, FAS, and SCD-1 after
adenovirus infection. Expression levels are normalized to glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) RT-PCR products. RT-PCR
products were analyzed by 0.7% agarose gel electrophoresis, and band
intensities were determined by imaging of ethidium bromide staining.
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action on adiponectin. In this regard, it is likely that ADD1/
SREBP1c plays a critical role, not only in the insulin-depend-
ent gene expression that coordinates fatty acids and glucose
metabolism but also in stimulating adiponectin expression to
improve the insulin sensitivity.
TNF expression is increased in the obese state and has been
implicated in obesity-linked insulin resistance (39–42). TNF
stimulates lipolysis, thus increasing plasma free fatty acids
and directly interfering with insulin signaling (40, 64). Like
adiponectin, ADD1/SREBP1c mRNA expression is markedly
FIG. 6. Regulation of adiponectin gene expression by nutrient and insulin. A, nutritional regulation of SREBP1, FAS, and adiponectin
expression. mRNA expression levels in adipose tissue from fed, fasted, and re-fed mice compared by Northern blot analysis. Mice (male C57BL/6)
were sacrificed after nutritional challenge, and total RNA was prepared from abdominal adipose tissue. The mice were divided into three groups.
Fed controls were allowed free access to food for 12 h (lane 1). The fasted group was denied access to food for 16 h (lane 2). The re-fed group was
allowed free access to food for 8 h after 16 h of fasting (lane 3). The expression levels of feeding, fasting, and refeeding groups were quantified and
normalized to 28 S rRNA. B, time-dependent effects of insulin on SREBP1, FAS, and adiponectin gene expression in 3T3-L1 adipocytes. Fully
differentiated 3T3-L1 adipocytes were incubated overnight in serum-free low glucose DMEM containing 0.5% BSA and treated with insulin (100
nM). mRNA levels of SREBP1 and adiponectin were examined by Northern blot. 28 S rRNA were used to normalize RNA loading. C, transactivation
of the mouse adiponectin promoter by ADD1/SREBP1c. Rat1-IR cells were cotransfected with pAdiponectin-984-Luc or pAdiponectin-410-Luc
reporter and ADD1/SREBP1c expression vector. After transfection, cells were incubated overnight in serum-free DMEM with 0.5% BSA and
treated with (lanes 2, 4 and 6) or without (lanes 1, 3 and 5) 100 nM insulin for 24 h. They were harvested and assayed for luciferase and
-galactosidase activity. D, induction of ADD1/SREBP1c binding to the mouse adiponectin promoter with insulin. ChIP assay of the mouse
adiponectin promoter. Fully differentiated 3T3 L1 cells were cultured in the presence or absence of insulin. They were cross-linked and
immunoprecipitated with polyclonal anti-ADD1/SREBP1c antibodies (lanes 2 and 3), and the immunoprecipitated DNA fragments were amplified
by PCR. Lane 4 shows the amplified adiponectin promoter, PPAR2 promoter, and GAPDH from 1% of input DNA. GAPDH fragments were
amplified to normalize input DNA.
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inhibited by TNF through its action in blocking insulin-de-
pendent activation of ADD1/SREBP1c expression (65). Conse-
quently, it has been suggested that selective down-regulation of
ADD1/SREBP1c in the adipose tissue of obese subjects contrib-
utes to the partitioning of free fatty acids between insulin-
sensitive organs, such as skeletal muscle and liver, where they
could impair insulin action via their lipotoxicity (66). These
notions may provide a clue about how TNF is able to decrease
adiponectin gene expression in adipocytes, because TNF re-
duces ADD1/SREBP1c expression. Of course, the regulatory
networks connecting extracellular signals to ADD1/SREPB1c
and adiponectin expression remain to be elucidated. Taken
together, these findings show that ADD/SREBP1c is an impor-
tant transcription factor mediating adiponectin regulation by
insulin and TNF in adipocytes. They also account for why
adiponectin gene expression is decreased in insulin-resistant
obese and diabetic subjects.
Rosiglitazone, a member of thiazolidinediones, enhances the
expression and secretion of adiponectin in db/db mice fed a
high fat diet as well as in wild-type mice and cultured 3T3-L1
adipocytes (25, 67). Transcriptional activation of PPAR is
stimulated by its ligands, thiazolidinediones, and increases
insulin sensitivity by reducing TNF and increasing adiponec-
tin expression (25). Iwaki et al. recently identified a functional
PPRE in the human adiponectin promoter that mediates acti-
vated PPAR-dependent adiponectin gene expression (30). We
have also mapped a similar PPRE that can be transactivated
by PPAR, in the mouse adiponectin promoter. Although we
found several putative binding sites for C/EBPs, we failed to
observe C/EBP-induced activation of the adiponectin pro-
moter. This finding is supported by the observation that adi-
ponectin expression in C/EBP-deficient cell lines continues to
be activated by PPAR (68). Of course, we cannot rule out the
possibility that other C/EBP isoforms such as C/EBP or -
contribute to adiponectin gene expression; indeed, it is possible
that both PPAR and ADD1/SREBP1c regulate adiponectin
gene expression in adipocytes to increase insulin sensitivity.
In summary, we have shown for the first time that ADD1/
SREBP1c transactivates the mouse adiponectin promoter and
stimulates adiponectin mRNA and protein expression in adi-
pocytes. We have also provided evidence that ADD1/SREBP1c
is responsible for insulin-dependent adiponectin gene expres-
sion. Because ADD1/SREBP1c is a key transcription factor
coordinating lipid and glucose metabolism in response to insu-
lin, it is possible that fine-tuning of ADD1/SREBP1c expression
in adipocytes exerts an effect on adiponectin expression. In-
creased understanding of the mechanisms regulating ADD1/
SREBP1c and adiponectin gene expression promises to contrib-
ute to the development of approaches to the treatment of
obesity and type 2 diabetes.
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